XOMA Royalty (NASDAQ:XOMA) Issues Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Posted by Brenda Bartman on May 12th, 2026

XOMA Royalty (NASDAQ:XOMA – Get Free Report) issued its quarterly earnings data on Tuesday. The biotechnology company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.02), FiscalAI reports. The business had revenue of $12.32 million for the quarter, compared to the consensus estimate of $13.91 million. XOMA Royalty had a net margin of 45.75% and a return on equity of 10.32%.

XOMA Royalty Stock Performance

XOMA stock traded up $0.25 during midday trading on Tuesday, hitting $41.75. The stock had a trading volume of 83,680 shares, compared to its average volume of 362,370. The firm has a market capitalization of $497.66 million, a price-to-earnings ratio of 28.60 and a beta of 0.90. XOMA Royalty has a 52 week low of $22.29 and a 52 week high of $42.81. The stock has a 50-day simple moving average of $33.63 and a 200 day simple moving average of $30.37. The company has a current ratio of 3.37, a quick ratio of 3.37 and a debt-to-equity ratio of 1.15.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in shares of XOMA Royalty by 4.6% during the third quarter. Vanguard Group Inc. now owns 668,111 shares of the biotechnology company’s stock valued at $25,749,000 after acquiring an additional 29,298 shares during the period. Opaleye Management Inc. raised its holdings in shares of XOMA Royalty by 14.7% in the fourth quarter. Opaleye Management Inc. now owns 292,590 shares of the biotechnology company’s stock valued at $7,780,000 after buying an additional 37,503 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of XOMA Royalty by 4.5% in the fourth quarter. Geode Capital Management LLC now owns 221,566 shares of the biotechnology company’s stock valued at $5,893,000 after buying an additional 9,589 shares during the last quarter. Woodline Partners LP increased its position in XOMA Royalty by 16.5% in the third quarter. Woodline Partners LP now owns 209,945 shares of the biotechnology company’s stock worth $8,091,000 after purchasing an additional 29,715 shares during the period. Finally, State Street Corp increased its position in XOMA Royalty by 4.7% in the fourth quarter. State Street Corp now owns 174,908 shares of the biotechnology company’s stock worth $4,651,000 after purchasing an additional 7,873 shares during the period. 95.92% of the stock is owned by institutional investors.

Analysts Set New Price Targets

XOMA has been the topic of several recent research reports. Leerink Partners reaffirmed an “outperform” rating on shares of XOMA Royalty in a research report on Tuesday, February 24th. HC Wainwright downgraded XOMA Royalty from a “buy” rating to a “neutral” rating and set a $39.00 price target on the stock. in a report on Thursday, April 30th. Zacks Research upgraded XOMA Royalty from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 8th. Lucid Cap Mkts downgraded XOMA Royalty from a “strong-buy” rating to a “hold” rating in a report on Monday, April 27th. Finally, TD Cowen upgraded XOMA Royalty to a “hold” rating in a report on Friday, February 13th. Two research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $53.75.

View Our Latest Research Report on XOMA

About XOMA Royalty

(Get Free Report)

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.